Keros Therapeutics (KROS) Tax Provisions (2020 - 2025)

Keros Therapeutics has reported Tax Provisions for 4 years, with the latest figure at -$1.5 million in Q4 2025.

• For the quarter ending Q4 2025, Tax Provisions fell 604.67% year-over-year to -$1.5 million; the trailing twelve-month figure through Dec 2025 stood at $4.9 million (up 1527.67% YoY), and the FY2025 full-year result was $4.9 million, up 1527.67% from the prior year.
• Tax Provisions for Q4 2025 stood at -$1.5 million, down from -$1.4 million in the prior quarter.
• The five-year high for Tax Provisions was $10.0 million in Q1 2025, with the low at -$2.2 million in Q2 2025.
• Historically, Tax Provisions has averaged $899250.0 across 3 years, with a median of $6000.0 in 2021.
• Annual changes were most pronounced in 2021 — Tax Provisions surged 129.07% — and 2025, when it tumbled 604.67%.
• Keros Therapeutics' Tax Provisions stood at $2.0 million in 2021, then slumped by 84.99% to $300000.0 in 2024, then plunged by 604.67% to -$1.5 million in 2025.
• The last three Tax Provisions figures came in at -$1.5 million (Q4 2025), -$1.4 million (Q3 2025), and -$2.2 million (Q2 2025), per Business Quant data.